Robotics
+3
Sep 6, 2026
Agility will be the only listed U.S. humanoid pure-play, with a factory rated for 10,000 robots a year and paid deployments at Amazon, GXO, Schaeffler, Toyota, and Mercado Libre. However, at $13.40/share, you're paying $4.51B for just $1.78M of FY2025 revenue.
Consumer
+1
Aug 24, 2026
A two-brand, share-gaining footwear business at ~12x earnings, ~40% ROE, and ~$1.1B of FCF, priced like it's done growing. Whether it's cheap or a value trap comes down to whether HOKA keeps its pricing power.
RVPH
+2
Aug 20, 2026
Reviva pushed its Phase 3 back a year, and the stock is down ~27% since my June write-up. Two developments matter more: (1) a patent filing that stretches exclusivity to 2046 and (2) evidence Teva has studied brilaroxazine since 2023.
BRUN
+5
Aug 16, 2026
Five quarterly updates on names from the write-up archive. I compare against guidance and discuss what actually matters underneath the headline numbers.
AWMLF
+1
Aug 13, 2026
A US$28M company owns the largest known undeveloped indium resource in the US. The US imports 100% of its indium, China controls 70% of supply, and the Pentagon has started soliciting purchases for the stockpile.

Write-ups and models on asymmetric stocks and macro themes. Built on 10+ years studying top investors/funds, and 500,000+ words of published guides.